WorstPills.org - Search Results for enoxaparin [injectable] (LOVENOX)

An expert, independent second opinion on more than 1,800 prescription drugs, over-the-counter medications, and supplements

Search Type: drug or dietary supplement name
Search Term: enoxaparin [injectable] (LOVENOX)

Worst Pills, Best Pills Newsletter Articles \| Additional Information from Public Citizen

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a secondary subject of discussion

Do Not Use the New Oral Blood Thinner Apixaban (ELIQUIS) [hide all summaries]
(June 2018)
Apixaban is a new oral anticoagulant (blood thinner) that was first approved by the FDA in 2012 for decreasing the risk of blood clots in certain patients. Find out why older anticoagulant drugs, such as warfarin (COUMADIN, JANTOVEN), are a better choice.
Do Not Use the New Blood Thinner Edoxaban (SAVAYSA) [hide all summaries]
(November 2017)
Learn why edoxaban, one of the new blood thinners approved by the FDA, is not the best option for preventing dangerous blood clots in patients with atrial fibrillation.
Emerging Risks With New Stroke Prevention Drugs [hide all summaries]
(April 2013)
Learn about three new drugs to prevent stroke – so new that their risks relative to those of a much older drug, warfarin (Coumadin), are unknown.

Search results below include Additional Information from Public Citizen where your selected drug is a secondary subject of discussion

FDA Should Give Oral Presentations at All Advisory Committee Meetings, Public Citizen Tells Agency [hide all summaries]
Agency experts should be required to give presentations at all future Food and Drug Administration (FDA) advisory committee meetings discussing specific products, Public Citizen said in a petition filed today.
Testimony before the FDA's Cardiovascular and Renal Drugs Advisory Committee Hearing on Ximelagatran--September 10, 2004 (HRG Publication #1706) [hide all summaries]
Testimony of Peter Lurie, MD, MPH, and Elizabeth Barbehenn, PhD of Public Citizen's Health Research Group, before the FDA's Cardiovascular and Renal Drugs Advisory Committee Hearing on Ximelagatran